RCRS Innovations files IPO draft papers with NSE Emerge to raise funds
ECONOMY & POLICY

RCRS Innovations files IPO draft papers with NSE Emerge to raise funds

RCRS Innovations, a manufacturer of lithium batteries and solar panels, announced that it has filed draft papers with NSE Emerge for an initial public offering (IPO) to raise funds for its expansion plans. The company, based in Noida, is looking to issue 48.24 lakh equity shares, each with a face value of Rs 10, according to a statement.

The company intends to use the net proceeds from the offering to meet its working capital requirements and increase its battery manufacturing capacity.

RCRS Innovations manufactures and markets lithium-ion batteries and solar panels under the EXEGI brand across two plants in the Delhi-NCR region. The company’s products are mainly used for clean energy storage and solar lighting. RCRSIL and its products hold over 20 certifications and test reports.

During the first nine months of the fiscal year 2023-24 (April-December), the company registered revenues of Rs 780.68 million and a profit after tax (PAT) of Rs 50.71 million. In comparison, for the full financial year 2022-23, it had generated revenues of Rs 670.80 million and PAT of Rs 10.35 million.

Corporate Capital Ventures is acting as the sole book running lead manager for the issue.

RCRS Innovations, a manufacturer of lithium batteries and solar panels, announced that it has filed draft papers with NSE Emerge for an initial public offering (IPO) to raise funds for its expansion plans. The company, based in Noida, is looking to issue 48.24 lakh equity shares, each with a face value of Rs 10, according to a statement. The company intends to use the net proceeds from the offering to meet its working capital requirements and increase its battery manufacturing capacity. RCRS Innovations manufactures and markets lithium-ion batteries and solar panels under the EXEGI brand across two plants in the Delhi-NCR region. The company’s products are mainly used for clean energy storage and solar lighting. RCRSIL and its products hold over 20 certifications and test reports. During the first nine months of the fiscal year 2023-24 (April-December), the company registered revenues of Rs 780.68 million and a profit after tax (PAT) of Rs 50.71 million. In comparison, for the full financial year 2022-23, it had generated revenues of Rs 670.80 million and PAT of Rs 10.35 million. Corporate Capital Ventures is acting as the sole book running lead manager for the issue.

Next Story
Infrastructure Urban

Mahindra Logistics Launches New Warehouse in Phaltan

Mahindra Logistics Ltd., one of India’s largest integrated logistics solutions providers, has inaugurated a new state-of-the-art warehousing facility in Phaltan, Maharashtra. This development enhances the company’s presence in one of India’s most rapidly growing industrial corridors.Spanning over 300,000 square feet, the newly operational facility has been developed as a dedicated logistics centre for Cummins India, a leading power solutions provider. The warehouse aims to streamline Cummins India’s nationwide operations by consolidating products from multiple sources into a centralise..

Next Story
Infrastructure Urban

Greaves Electric Mobility Names Vikas Singh as MD

Greaves Electric Mobility Limited (GEML), the electric mobility arm of Greaves Cotton Limited, has appointed Mr Vikas Singh as its new Managing Director, effective 2nd June 2025. In his new role, Mr Singh will lead the company’s next phase of growth, with all key members of the current management team reporting directly to him.Mr Singh brings with him extensive leadership experience from some of India’s most competitive consumer-facing industries. Known for his ability to steer companies through regulated environments, he has demonstrated a strong capacity to drive organisational transform..

Next Story
Infrastructure Urban

OneSource, Xbrane Partner for Global Biosimilar Supply

OneSource Specialty Pharma Limited, a multi-modality specialty pharmaceutical contract development and manufacturing organisation (CDMO), has announced a strategic manufacturing partnership with Sweden-based Xbrane Biopharma AB (Nasdaq: XBRANE), a leading biotechnology firm. The collaboration will focus on the commercial production of Xbrane’s biosimilar portfolio.Xbrane’s biosimilar pipeline targets an estimated EUR 23 billion in annual peak sales of the reference biologics. Its lead candidate, Ximluci—a biosimilar of ranibizumab—has already received market authorisation in Europe and..

Advertisement

Advertisement

Subscribe to Our Newsletter

Get daily newsletters around different themes from Construction world.

STAY CONNECTED

Advertisement

Advertisement

Advertisement

Advertisement

Talk to us?